GLP-1 receptor agonists reduce caloric intake through appetite suppression and slow gastric emptying. However, they do not directly increase energy expenditure or selectively mobilise stored fat. Combining GLP-1 compounds with peptides that act through complementary mechanisms — lipolysis stimulation, thermogenesis, growth hormone axis activation — is an active area of research in metabolic science.
The most commonly researched combination in the metabolic peptide space. GLP-1 agonists (Semaglutide, Tirzepatide) suppress appetite and caloric intake; AOD-9604 directly stimulates beta-3 adrenergic receptor-mediated lipolysis in adipose tissue, mobilising stored fat for oxidation. The mechanisms are non-overlapping and potentially additive.
Research protocol context: Semaglutide 0.5–1 mg weekly + AOD-9604 500 mcg daily. Both available from QSC with Janoshik COA.
While not yet in clinical combination trials, researchers studying the full spectrum of metabolic receptor pharmacology may examine Retatrutide (GLP-1+GIP+GCGR) alongside Cagrilintide (amylin analog, AMY receptor). These compounds act through entirely separate systems: incretin/glucagon vs amylin/calcitonin receptor axes. CagriSema (Semaglutide + Cagrilintide) Phase 3 data demonstrates the additive potential of combining amylin and GLP-1 agonism.
GLP-1 agonists reduce total body weight but some portion of weight loss is lean mass. CJC-1295 + Ipamorelin co-administration stimulates pulsatile growth hormone release, which promotes lean mass preservation and fat oxidation through the GH/IGF-1 axis. This combination is studied for body composition optimisation in contexts where maintaining muscle mass alongside fat reduction is a research objective.
| Compound | Mechanism | QSC Form |
|---|---|---|
| Semaglutide | GLP-1R agonist | 2 mg vials |
| Tirzepatide | GLP-1R + GIPR | 5 mg vials |
| Retatrutide | GLP-1R + GIPR + GCGR | 10 mg vials |
| AOD-9604 | Beta-3 adrenergic / lipolysis | 5 mg vials |
| CJC-1295 + Ipamorelin | GHRH + GHS-R1a | Blend vials |
| Cagrilintide | AMY1R/2R/3R amylin analog | 5 mg vials |
This page is for educational and research purposes only. All products sold by QSC are labelled for research use only and are not intended for human consumption. Nothing on this page constitutes medical advice.